Literature DB >> 26414610

Orthotopic urinary diversion.

Siamak Daneshmand1.   

Abstract

PURPOSE OF REVIEW: Orthotopic urinary diversion has been performed for more than 30 years. Although it is considered to be the gold standard form of diversion in many centers of expertise, however it is uncommonly performed outside these institutions. The purpose of this article is to review the current indications and outcomes of orthotopic diversion with a focus on male patients and to explore potential barriers to wider dissemination of the technique. RECENT
FINDINGS: Approximately 75% of patients undergoing radical cystectomy today are candidates for orthotopic diversion and in the absence of absolute contraindications, very few patients chose to undergo an ileal conduit for personal reasons. In a recent quality of life study, the orthotopic neobladder was better than ileal conduit in terms of global health status and physical functioning. In a prospective randomized trial comparing a refluxing versus nonrefluxing neobladder, there was no difference in renal function after 3 years. There is currently insufficient evidence to suggest improved perioperative outcomes with the use of minimally invasive techniques.
SUMMARY: There are very few absolute contraindications for an orthotopic neobladder, which remains the gold standard form of diversion at many centers of expertise. Surgeon experience and thorough preoperative counseling with realistic expectations can ensure optimal outcomes and patient satisfaction.

Entities:  

Mesh:

Year:  2015        PMID: 26414610     DOI: 10.1097/MOU.0000000000000226

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  8 in total

1.  Orthotopic bladder substitution for bladder cancer patients undergoing radical cystectomy: A call to action.

Authors:  Adrian S Fairey; Ryan Mclarty
Journal:  Can Urol Assoc J       Date:  2018-06       Impact factor: 1.862

2.  A Qualitative Assessment of Patient Satisfaction with Radical Cystectomy for Bladder Cancer at a Single Institution: How Can We Improve?

Authors:  Lukas Hockman; Jacob Bailey; Jacob Sanders; Catherine Muzzey; Mark Wakefield; Amy Christensen; Katie Murray
Journal:  Res Rep Urol       Date:  2020-10-08

3.  Urinary tract infections following radical cystectomy and urinary diversion: a review of 1133 patients.

Authors:  Thomas G Clifford; Behrod Katebian; Christine M Van Horn; Soroush T Bazargani; Jie Cai; Gus Miranda; Siamak Daneshmand; Hooman Djaladat
Journal:  World J Urol       Date:  2018-01-25       Impact factor: 4.226

4.  Percutaneous Management of a Pyocystic Fistulizing Continent Urinary Diversion.

Authors:  Michael C Phung; Benjamin R Lee; Joel T Funk
Journal:  J Endourol Case Rep       Date:  2017-11-01

5.  Surgical techniques, oncologic and functional outcomes of two types of modified ileal orthotopic neobladders.

Authors:  Qinxin Zhao; Feiya Yang; Han Hao; Xinfei Li; Liyuan Wu; Xuesong Li; Nianzeng Xing
Journal:  Transl Androl Urol       Date:  2021-07

6.  The relationship between type of urinary diversion and quality of life after radical cystectomy: Ileal conduit versus orthotopic bladder.

Authors:  Mohamed S Elbadry; Ahmed Issam Ali; Ali Hassan; Kieran David Clement; Ahmed Rashed Hammady; Abdalla Abdbelaal; Nady Mounir Barsoum; Mohamed Abd Elmalek Hassan; Ahmed H Gabr
Journal:  BJUI Compass       Date:  2020-06-19

Review 7.  Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.

Authors:  Marga Garrido Siles; Antonio López-Beltran; Paula Pelechano; Ana María García Vicente; Regina Gironés Sarrió; Eva González-Haba Peña; Alfredo Rodríguez Antolín; Almudena Zapatero; José Ángel Arranz; Miguel Ángel Climent
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

Review 8.  Urinary diversion after pelvic exenteration for gynecologic malignancies.

Authors:  Carlos Martínez-Gómez; Martina Aida Angeles; Alejandra Martinez; Bernard Malavaud; Gwenael Ferron
Journal:  Int J Gynecol Cancer       Date:  2020-11-23       Impact factor: 3.437

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.